M&A news

Inke Acquires Pharmabinoid, Expanding

Pharmabinoid acquired by undefined

AcquisitionManufacturing

Get the full Pharmabinoid company profile

Access contacts, investors, buying signals & more

Open in Dashboard
Pharmabinoid logo
Acquired

Pharmabinoid

Manufacturing

Undisclosed amount

December 19, 2025

?
Acquirer

Unknown

Inke has acquired Pharmabinoid, a manufacturer and wholesaler of cannabinoids and cannabinoid-based products, for an undisclosed amount. This corporate acquisition marks a significant expansion for Inke into the rapidly evolving cannabinoid market. The transaction involves Inke buying Pharmabinoid outright, integrating its operations and product lines into Inke's existing structure.

Pharmabinoid has established itself as a key player in the production and distribution of various cannabinoid compounds and related finished goods. Its expertise spans the entire supply chain, from raw material processing to the wholesale of specialized cannabinoid ingredients and consumer-ready products. This acquisition is strategic for Inke, aiming to leverage Pharmabinoid's specialized manufacturing capabilities and market access within the cannabinoid sector. The move is expected to broaden Inke's portfolio and strengthen its position in areas requiring advanced ingredient solutions.

The integration of Pharmabinoid into Inke is anticipated to generate several synergies. Inke stands to benefit from Pharmabinoid's established production infrastructure and technical know-how in cannabinoid extraction and formulation. Conversely, Pharmabinoid will gain access to Inke's broader operational resources and potential distribution networks, which could accelerate its growth and market penetration. This combination is expected to enhance efficiency, streamline supply chains, and foster innovation in product development across both entities.

This transaction is a direct corporate acquisition, where Inke has purchased Pharmabinoid, rather than a funding round or investment. It represents a strategic consolidation designed to create a more comprehensive and competitive entity in the specialized ingredients market.

Looking ahead, the combined entity is positioned to capitalize on the increasing demand for high-quality cannabinoid products and ingredients. The acquisition is expected to enable Inke to offer a more diverse range of specialized solutions, serving a wider customer base and driving future growth in this dynamic industry.

No buying signals identified yet.

Unlock GTM signals

Discover Pharmabinoid's tech stack and active buying intent.

View GTM signals

Unlock key decision-makers

Get direct access to the decision-makers at Pharmabinoid.

Unlock decision-makers